In another trial treating metastatic NPC patients with Endostar and cisplatin-based chemotherapy [17], an ORR of 77.8% was achieved, and the median PFS was 12 months, suggesting that the combination of a VEGF inhibitor and chemotherapy might yield synergistic efficacy for the treatment of metastatic NPC. Here, VEGFA is linked to nasopharyngeal carcinoma.